

NKOTB: New and Emerging Roles for GLP-1-based Medications

Devra Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy

Learning Objectives

At the conclusion of this presentation, pharmacists should be able to:

List recent FDA-approved indications for GLP-1-based medications.

Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease.

Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications.

Disclosures

- No actual or potential conflict of interest with the content of this presentation.
- This activity may contain discussion of unlabeled/unapproved use of drugs.
- Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, precautions, and warnings.
- The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy.

Learning Objectives

At the conclusion of this presentation, pharmacists should be able to:

List recent FDA-approved indications for GLP-1-based medications.

Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease.

Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications.

GLP-1-based Medications with FDA-Approval for **T2DM** in Adults

- Exenatide – 4/2005 (Byetta), 1/2012 (Bydureon), 11/2024 (generic)
 - Liraglutide – 1/2010 (Victoza), 12/2024 (first generic)
 - Albiglutide – 4/2014 (Tanzeum, discontinued 2017)
 - Dulaglutide – 9/2014 (Trulicity)
 - Lixisenatide – 7/2016 (Adlyxin, discontinued 2023)
 - Semaglutide – 12/2017 (Ozempic), 9/2019 (Rybelsus)
 - Tirzepatide – 5/2022 (Mounjaro)
-
- Insulin glargine-lixisenatide – 11/2016 (Soliqua 100/33)
 - Insulin detemir-liraglutide – 11/2016 (Xultophy 100/3.6)

GLP-1-based Medications with FDA-Approval for **Overweight & Obesity** in Adults

- Liraglutide – 12/2014 (Saxenda), generic 8-2025
- Semaglutide – 6/2021 (Wegovy)
- Tirzepatide – 11/2023 (Zepbound)

Are there other FDA-approved indications?

AUDIENCE POLL

Which of the following GLP-1-based medication has an FDA indication for reducing risk sustained eGFR decline, end-stage kidney disease and CV death in adults with type 2 diabetes mellitus and CKD?

- A. dulaglutide
- B. liraglutide
- C. semaglutide
- D. tirzepatide

AUDIENCE POLL

Which of the following GLP-1-based medication has an FDA indication for management of obstructive sleep apnea (OSA)?

- A. dulaglutide
- B. liraglutide
- C. semaglutide
- D. tirzepatide

GLP-1-Based Medications – FDA Approved Indications

Indication → Medication ↓	T2DM	Weight Management	Obstructive Sleep Apnea (OSA)	CV Risk Reduction	Kidney Risk Reduction	Metabolic dysfunction–Associated Steatohepatitis (MASH)	Approved in Pediatric Population
Dulaglutide (Trulicity)	✓	-	-	✓	-	-	✓ 10 years and older (T2DM)
Exenatide (Bydureon, Byetta)	✓	-	-	-	-	-	✓ 10 years and older (T2DM; Bydureon only)
Lixisenatide (Adlyxin)	✓	-	-	-	-	-	-

GLP-1-Based Medications – FDA Approved Indications

Indication → Medication ↓	T2DM	Weight Management	Obstructive Sleep Apnea (OSA)	CV Risk Reduction	Kidney Risk Reduction	Metabolic dysfunction–Associated Steatohepatitis (MASH)	Approved in Pediatric Population
Liraglutide (Saxenda, Victoza)	✓ (Victoza)	✓ (Saxenda)	-	✓ (Victoza)	-	-	✓ Victoza: 10 yrs & older (T2DM) Saxenda: 12 yrs & older (obesity)
Semaglutide (Ozempic, Rybelsus, Wegovy)	✓ (Ozempic and Rybelsus)	✓ (Wegovy)	-	✓ (Ozempic, Rybelsus, Wegovy)	✓ (Ozempic)	✓ (Wegovy)	✓ Wegovy: 12 yrs & older (obesity)
Tirzepatide (Mounjaro, Zepbound)	✓ (Mounjaro)	✓ (Zepbound)	✓ (Zepbound)	-	-	-	-

Learning Objectives

At the conclusion of this presentation, pharmacists should be able to:

List recent FDA-approved indications for GLP-1-based medications.

Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease.

Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications.

GLP-1: secreted by L-cells in small intestines (mostly in lower jejunum and ileum)

*glucagon-like peptide 1

GI tract


- ↓ gastric emptying



Brain

- ↑ satiety
- ↓ food intake

Main Effects of GLP-1



Pancreas


- ↑ glucose-dependent insulin secretion
- ↓ glucagon



Body

- ↑ insulin sensitivity (indirect effect)

Images: Flaticon.com



Learning Objectives


At the conclusion of this presentation, pharmacists should be able to:


List recent FDA-approved indications for GLP-1-based medications.

Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease.

Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications.

GLP-1-based Medications and Cardiovascular Protection





Giugliano D et al. *Cardiovasc Diabetol*. 2021 Sep 15;20(1):189.

Semaglutide 2.4 mg Cardiovascular Outcomes (SELECT RCT)

- **Population:** 17,604 adults 45 years or older with pre-existing CVD, BMI 27+, and **NO hx of diabetes**
- **Intervention:**
 - Semaglutide 2.4 mg SC QW
 - Placebo SC QW
- **Outcome:** Primary endpoint – composite of:
 - First occurrence of death from CV causes
 - Nonfatal MI
 - Nonfatal stroke


Lincoff AM et al. *N Engl J Med* 2023;389(24):2221-2232.

Time-to-First-Event Analysis for Primary and Confirmatory Secondary Efficacy End Points.

Semaglutide 2.4 mg SELECT RCT

45 years of age or older with preexisting CVD (but without DM) and BMI ≥ 27

8803 semaglutide, 8801 placebo
~ 3 years



Change in weight from baseline semaglutide: -9.39%
placebo: -0.88%

Treatment difference: -8.5%

↓ CV composite endpoint, heart failure composite endpoint, and death from any causes


AM Lincoff et al. N Engl J Med 2023. DOI: 10.1056/NEJMoa2307563

Oral Semaglutide – SOUL RCT

- **Population:** 9650 patients 50 years and older with T2DM, A1c 6.5-10%, and known ASCVD, CKD, or both
- **Intervention:**
 - Semaglutide 14 mg PO daily, in addition to standard care
 - Placebo PO daily in addition to standard care
- **Outcome:** Primary endpoint – MACE, a composite of death from CV causes, nonfatal MI, and nonfatal stroke
 - Secondary outcomes – major kidney disease events

McGuire DK et al. N Engl J Med 2025;392(20):2001-2012.

A Major Adverse Cardiovascular Events



No. at Risk

Placebo	4825	4718	4583	4455	4322	4194	4101	3727	2517	1346
Oral semaglutide	4825	4743	4635	4542	4438	4346	4239	3831	2555	1346

- Oral semaglutide associated with a significantly lower risk of MACE than placebo
- Effect of PO semaglutide on MACE appeared to be larger among participants with A1c > 8%
- Trial population may not be representative of the global population with T2DM (~30% women, ~3% Black)

McGuire DK et al. *N Engl J Med* 2025;392(20):2001-2012.

GLP-1-based Medications and Obstructive Sleep Apnea (OSA)



image: Flaticon.com

Tirzepatide in OSA (SURMOUNT RCT)

- **Population:** 469 adults with moderate-to-severe OSA and obesity; two Phase 3 RCTs
 - Patients had to have at least 15 apneic–hypopneic events per hour, BMI $\geq$ 30, without diabetes
- **Intervention:**
 - Maximum tolerated dose of tirzepatide (10 mg or 15 mg) SC QW
 - Placebo SC QW
 - Both arms included reduced-calorie diet and increased physical activity
- **Outcome:** Primary end point: change from baseline in apnea–hypopnea index (AHI: number of apneas and hypopneas during an hour of sleep)

Malhotra A et al. *N Engl J Med* 2024;391(13):1193-1205.

Tirzepatide in OSA (SURMOUNT RCT)

Trial 1

- Participants **NOT receiving PAP** therapy
- 234 adults
- Mean age: 48 years old
- 67% men
- Mean AHI: ~50 events per hour
- Mean BMI: 39
- Without DM

Trial 2


- Participants **receiving PAP** therapy
- 235 adults
- Mean age: 52 years old
- 72% men
- Mean AHI: ~50 events per hour
- Mean BMI: 39
- Without DM

PAP = positive airway pressure

Malhotra A et al. *N Engl J Med* 2024;391(13):1193-1205.

- ~50% reduction in AHI
- All key secondary endpoints also favored tirzepatide
- Common ADEs were gastrointestinal in nature
- Authors intend to further study clinical outcomes


Malhotra A et al. *N Engl J Med* 2024;391(13):1193-1205.



GLP-1-based Medications and Chronic Kidney Disease (CKD)



image: Flaticon.com




Sasaki T et al. *Nephrol Dial Transplant*. 2025 Sep 22:gfa193.


Semaglutide in CKD (FLOW RCT)

- **Population:** 3533 participants with T2DM & CKD (eGFR 50-75 mL/min/1.73 m² and UACR >100 and <5000) receiving ACEI or ARB; mean age = 67, 70% men
- **Intervention:**
 - Semaglutide 1 mg SC QW
 - Placebo SC QW
- **Outcome:** Primary endpoints – major kidney disease events, a composite of:
 - Onset of kidney failure (initiation of dialysis, kidney transplantation, eGFR < 15 mL/min/1.73 m²)
 - 50% reduction or more in eGFR from baseline
 - Death from kidney or CV-related causes

Perkovic V et al. *N Engl J Med* 2024;391(2):109-121.


A First Major Kidney Disease Event**No. at Risk**

Placebo	1766	1736	1682	1605	1516	1408	1048	660	354
Semaglutide	1767	1738	1693	1640	1572	1489	1131	742	392


B First Kidney-Specific Component Event**No. at Risk**

Placebo	1766	1736	1682	1605	1516	1408	1048	660	354
Semaglutide	1767	1738	1693	1640	1572	1489	1131	742	392


- Semaglutide reduced risk of clinically important kidney outcomes
- Study did not assess combination therapy (SGLT-2 inhibitors, MRAs, etc)
- Majority of participants (~66%) were White

Perkovic V et al. *N Engl J Med* 2024;391(2):109-121.**C Death from Cardiovascular Causes****No. at Risk**


Placebo	1766	1737	1697	1641	1601	1544	1185	772	437
Semaglutide	1767	1739	1703	1665	1627	1583	1234	838	460

D Total eGFR Slope**No. at Risk**

Placebo	1766	1663	1573	1609	1490	1441	1284	876	609	199
Semaglutide	1766	1665	1590	1606	1521	1468	1345	952	651	218

E First Major Cardiovascular Event**No. at Risk**

Placebo	1766	1721	1663	1583	1535	1478	1133	731	418
Semaglutide	1767	1725	1672	1622	1575	1515	1176	793	430

F Death from Any Cause**No. at Risk**

Placebo	1766	1737	1697	1641	1601	1544	1185	772	437
Semaglutide	1767	1739	1703	1665	1627	1583	1234	838	460

Perkovic V et al. *N Engl J Med* 2024;391(2):109-121.

GLP-1-based Medications and Metabolic Dysfunction-Associated Steatohepatitis (MASH)






image: Flaticon.com

Pathogenesis of Metabolic Dysfunction-Associated Liver Disease



Abushamat LA et al. *Clin Gastroenterol Hepatol*. 2024 Aug;22(8):1565-1574.




Semaglutide in MASH (ESSENCE RCT)


- **Population:** 1197 adults with biopsy-defined Metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis stage 2 or 3
 - Excluded participants with other chronic liver diseases, high alcohol use, or recent GLP-1RA therapy
- **Intervention:**
 - Semaglutide 2.4 mg SC QW
 - Placebo SC QW x240 weeks
 - Planned interim analysis at 72 weeks
- **Outcome:** Primary endpoints – resolution of steatohepatitis with no worsening of liver fibrosis, reduction in liver fibrosis with no worsening of steatohepatitis

Sanyal AJ et al. *N Engl J Med* 2025;392(21):2089-2099.

A Resolution of Steatohepatitis with No Worsening of Liver Fibrosis



B Reduction in Liver Fibrosis with No Worsening of Steatohepatitis



Sanyal AJ et al. *N Engl J Med* 2025;392(21):2089-2099.

- Results from planned interim analysis of first 800 participants
- Results focused on histological improvements; clinical improvements will be further studied
- Improved glycemic control, weight loss, and insulin resistance with semaglutide

Putting it All Together

- Patient selection
- Early initiation of medication in the course of T2DM
- Balance efficacy with warnings, ADRs, DDIs, etc.
- Guidelines recommendations

Guidelines Recommendations

- American Diabetes Association (ADA)'s Standards of Medical Care for Diabetes
- KDIGO–ADA Consensus Guideline for Diabetes Management in Chronic Kidney Disease
- American College of Cardiology

Session Code for CE Credit: